Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL567648 | 0.92 | MEN1 (0.36) | NOS1NOS3NOS2MEN1GAA | |
| SCHEMBL567296 | 0.85 | NOS1 (0.36) | NOS1NOS3NOS2MEN1GAA | |
| SCHEMBL25353655 | 0.81 | NOS1 (0.36) | NOS1NOS3NOS2MEN1GAA | |
| SCHEMBL567299 | 0.80 | MAOA (0.47) | MEN1GAAKMT2AMAOAMAOB | |
| SCHEMBL567461 | 0.77 | MEN1 (0.34) | NOS1NOS3NOS2MEN1GAA | |
| SCHEMBL21122117 | 0.74 | MEN1 (0.39) | NOS1NOS3NOS2MEN1GAA | |
| Methylamine SCHEMBL28388761 | 0.72 | NOS1 (0.39) | NOS1NOS3NOS2MEN1GAA | |
| SCHEMBL30074519 | 0.71 | CTSK (0.38) | NOS1NOS3NOS2MEN1GAA | |
| SCHEMBL5216229 | 0.71 | CTSK (0.38) | NOS1NOS3NOS2MEN1GAA | |
| SCHEMBL4670568 | 0.71 | MEN1 (0.56) | MEN1GAAKMT2AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102448941-B | The isoquinilone derivatives replaced | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2016-04-06 | — | — | CN | disclosed |
| EP-2444395-B1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | WESTERN THERAPEUTICS INST INC D (JP) | 2016-01-06 | — | — | EP | disclosed |
| US-8951997-B2 | Substituted isoquinoline derivative | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2015-02-10 | — | — | US | disclosed |
| EP-2444395-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. Western Therapeutics Institute, Inc. (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. WESTERN THERAPEUTICS INSTITUTE, INC (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | SULT1A1, SULT1E1, SULT2A1 | NOS1 418/4885NOS3 314/4885NOS2 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.